Molecular structure of TG101348, CAS Number: 936091-26-8
TG101348 (CAS 936091-26-8)
See product citations (6)
Alternate Names:
Fedratinib; SAR302503, N-tert-butyl-3-(5-methyl-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino)pyrimidin-4-ylamino)benzenesulfonamide
Application:
TG101348 is a selective inhibitor of JAK2 tyrosine kinase
CAS Number:
936091-26-8
Purity:
≥98%
Molecular Weight:
524.68
Molecular Formula:
C27H36N6O3S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
TG101348 is a molecule that acts as an inhibitor of the Janus kinase 2 (JAK2) enzyme, which is in managing the differentiation, proliferation, and survival of hematopoietic stem cells. The compound has been the focus of in vitro research studies exploring its effects on cell growth in various cell models, including those for chronic myelogenous leukemia (CML) and polycythemia vera (PV), where it demonstrated dose-dependent growth inhibition. By binding to and inhibiting JAK2, TG101348 effectively reduces signaling through pathways that are normally mediated by this enzyme.
TG101348 (CAS 936091-26-8) References
- Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. | Pardanani, A., et al. 2011. J Clin Oncol. 29: 789-96. PMID: 21220608
- TG101348, a selective JAK2 antagonist, ameliorates hepatic fibrogenesis in vivo. | Akcora, BÖ., et al. 2019. FASEB J. 33: 9466-9475. PMID: 31100032
- Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. | Roskoski, R. 2020. Pharmacol Res. 152: 104609. PMID: 31862477
- Management of myelofibrosis after ruxolitinib failure. | Harrison, CN., et al. 2020. Ann Hematol. 99: 1177-1191. PMID: 32198525
- Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. | Talpaz, M. and Kiladjian, JJ. 2021. Leukemia. 35: 1-17. PMID: 32647323
- Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. | Tefferi, A. 2021. Am J Hematol. 96: 145-162. PMID: 33197049
- Novel therapeutics in myeloproliferative neoplasms. | Venugopal, S. and Mascarenhas, J. 2020. J Hematol Oncol. 13: 162. PMID: 33267911
- Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis. | Pardanani, A., et al. 2021. Br J Haematol. 195: 244-248. PMID: 34331348
- Managing patients with myelofibrosis and thrombocytopenia. | Yilmaz, M. and Verstovsek, S. 2022. Expert Rev Hematol. 15: 233-241. PMID: 35316110
- A Comprehensive Overview of Globally Approved JAK Inhibitors. | Shawky, AM., et al. 2022. Pharmaceutics. 14: PMID: 35631587
- Management of Myeloproliferative Neoplasms in the Molecular Era: From Research to Practice. | Pettit, K., et al. 2022. Am Soc Clin Oncol Educ Book. 42: 1-19. PMID: 35658498
- Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders. | Roskoski, R. 2022. Pharmacol Res. 183: 106362. PMID: 35878738
- Pharmacogenomic landscape of head and neck squamous cell carcinoma informs precision oncology therapy. | Gu, Z., et al. 2022. Sci Transl Med. 14: eabo5987. PMID: 36070368
Inhibitor of:
1700020N15Rik, Ang-2, Bpifa6, CD2BP2, Ckt2, DCIR3, Erythroid lineage, Fc ε RIγ, G-CSFR, G6b_AU023871, GBP3, Gm5894, GPR172C, IFN-α/βRβ, IFN-α13, IFN-α6, IFN-τ, IL-10Rβ, IL-21R, IL-22Rα2, IL-28R, IL-7, JAK2, JAKMIP2, JAKMIP3, JFC1, KSHV ORF 72, NKG2-D, Olr1128, Olr113, Olr1169, Olr560, Olr665, OTTMUSG00000011262, OTTMUSG00000011265, RAG-1, RT1-Db1, and SOCS-5.Activator of:
EID-3, IFN-α/βRα, KIR2DS4, and PIK3IP1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TG101348, 5 mg | sc-364740 | 5 mg | $207.00 | |||
TG101348, 25 mg | sc-364740A | 25 mg | $515.00 |